Leukemia Treatment Market by Leukemia Type (Chronic Leukemia, Chronic Lymphatic Leukemia, Chronic Myeloid Leukemia, Acute Leukemia, Acute Lymphatic Leukemia, Acute Myeloid Leukemia, and Others), by Therapy (Chemotherapy, Biological Therapy, Radiation Therapy, Targeted Therapy, and Other), and Geography.  

Leukemia Treatment Market size was valued at USD 14.09 billion in 2021 and is expected to reach USD 26.08 billion by 2028, at a CAGR of 7.9% during the forecast period 2022-2028. Abnormal white blood cells beginning in the bone marrow of blood forming tissues results in a group of cancers collectively called as Leukemia. Leukemia is a cancer of blood-forming tissues in the body. Treatment of leukemia is done by blood transfusion, immunotherapy, bone marrow transplantation, radiation therapy and chemotherapy, biological therapy, targeted therapy, stem cell transplant. The drugs that are available in the market include the following: Gleevec, Bosulif, Sprycel, Iclusig etc. Bosutinib, omapro, quizartinib, graspa, and marquibo among others are the pipeline drugs under clinical trials yet to be launched with a promising potential to treat leukemia with minimal side effects. Based on the epidemiological factors, leukemia is forecasted to be more predominant in whites when compared to people of other racial or ethnic groups due to high incidence and mortality rates. Furthermore, exposure to radiation with genetic and environmental factors play a prominent role in increasing the prevalence of leukemia. Generally, men are more likely to develop leukemia than women. The risk of leukemia is majorly associated with age. The occurrence of leukemia is high in men and women aging over 66 years. Adults, both men and women normally aged in between 75 to 84 are more prevalent to the different types of leukemia such as chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. The prevalent rate of acute lymphocytic leukemia is high among 1 to 4 year old children and it is nearly eight times more than the young adults aging 20 and 24.